Spero Therapeutics, Inc. - Common Stock, Par Value $0.001 (SPRO)

Historical Holders from Q4 2017 to Q4 2024

Symbol
SPRO on Nasdaq
CUSIP
84833T103
Type / Class
Equity / Common Stock, Par Value $0.001
Shares outstanding
56M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
15.7M
Holdings value
$16.1M
% of all portfolios
0%
Grand Portfolio weight change
+0%
Number of holders
50
Number of buys
21
Number of sells
-17
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Spero Therapeutics, Inc. - Common Stock, Par Value $0.001 (SPRO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
GSK plc 16.4% $6.8M 9.19M GSK PLC Mar 27, 2025

Institutional Holders of Spero Therapeutics, Inc. - Common Stock, Par Value $0.001 (SPRO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q4 15.7M $16.1M +$401K $1.03 50
2024 Q3 12.3M $16.5M -$2.04M $1.34 45
2024 Q2 13.9M $18M +$23.1K $1.30 46
2024 Q1 13.7M $23.6M -$3.61K $1.72 54
2023 Q4 13.3M $19.6M +$228K $1.47 44
2023 Q3 14.2M $17.2M -$231K $1.21 52
2023 Q2 14.4M $20.8M +$16.8K $1.45 55
2023 Q1 14.2M $20.6M -$483K $1.45 45
2022 Q4 14.2M $24.6M -$13.8M $1.73 57
2022 Q3 19.2M $38.3M -$3.19M $2.00 58
2022 Q2 20.7M $15.4M -$13.8M $0.74 57
2022 Q1 20.2M $176M +$3.32M $8.70 96
2021 Q4 19.8M $316M +$2.06M $16.01 79
2021 Q3 18.4M $338M +$16.4M $18.41 87
2021 Q2 16.1M $225M -$17.5M $13.96 83
2021 Q1 17.4M $256M +$11.6M $14.72 87
2020 Q4 18.6M $360M +$25.8M $19.39 85
2020 Q3 16.8M $187M +$55.2M $11.16 75
2020 Q2 11.8M $159M +$6.84M $13.53 75
2020 Q1 10.9M $87.9M +$4.24M $8.08 56
2019 Q4 10.8M $104M +$4.17M $9.61 60
2019 Q3 10.4M $110M -$2.84M $10.60 56
2019 Q2 10.6M $122M +$15.8M $11.51 59
2019 Q1 9.27M $119M +$3.65M $12.81 53
2018 Q4 9.1M $56M -$16.9M $6.15 48
2018 Q3 10.7M $113M +$24.5M $10.51 50
2018 Q2 8.12M $119M +$21.7K $14.67 40
2018 Q1 7.69M $110M -$787K $14.25 31
2017 Q4 7.76M $91.1M +$91M $11.75 34